Patients whose tumors were PD-L1 positive and sTIL-high (≥30%) had a numerically higher pCR rate of 57% than those with PD-L1 positive but sTIL intermediate or low cancers (pCR rate 50%) or PD-L1 negative cancers (pCR rate 32%), but these differences did not reach statistical significance (p = 0.302, two-sided Fisher’s exact test). The gene discussed is CD274; the disease is cancer.